Business
Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights
Enrolled first three FTD-GRN patients in Cohort 3 of ongoing upliFT-D study Treated first FTD-C9orf72 patient with Dose 2 PBFT02 in Cohort 4 of upliFT-D study On track to report updated interim safety and biomarker data from upliFT-D and obtain regulatory feedback on FTD-GRN registrational trial design in 1H 2026 Advancing differentiated preclinical program for Huntington’s with clinical candidate selection expected in 2H 2026 Cash runway through 1Q 2027 PHILADELPHIA, March 03, 2026 (GLOBE NEWSW
About this update from Passage Bio, Inc.
[{"type":"image","alt":"Passage Bio","displaySize":"","headline":null,"caption":"Passage Bio","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":86,"url":"https://media.zenfs.com/en/globenewswire.com/b3c0c02f5e492ae038a6a6abc1f66d66"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/voTmQbQLiNqTa.rw6jMsmQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b3c0c02f5e492ae038a6a6abc1f66d66","width":300,"height":86}},"lazy":false},{"type":"text","content":"Enrolled first three FTD-GRN patients in Cohort 3 of ongoing upliFT-D study","length":75,"tagName":"p"},{"type":"text","content":"Treated first FTD-C9orf72 patient with Dose 2 PBFT02 in Cohort 4 of upliFT-D study","length":82,"tagName":"p"},{"type":"text","content":"On track to report updated interim safety and biomarker data from upliFT-D and obtain regulatory feedback on FTD-GRN registrational trial design in 1H 2026","length":155,"tagName":"p"},{"type":"text","content":"Advancing differentiated preclinical program for Huntington’s with clinical candidate selection expected in 2H 2026","length":115,"tagName":"p"},{"type":"text","content":"Cash runway through 1Q 2027","length":27,"tagName":"p"},{"type":"text","content":"PHILADELPHIA, March 03, 2026 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported financial results for the fourth quarter and year ended December 31, 2025, and provided recent business highlights.","length":337,"tagName":"p"},{"type":"text","content":"“We are proud of the progress made in 2025 as we meaningfully advanced our PBFT02 clinical program for the treatment of genetic forms of frontotemporal dementia,” said Will Chou, M.D., president and chief executive officer of Passage Bio. “As we enter 2026, we are excited by the strong enrollment momentum in our upliFT-D clinical study and look forward to sharing important data and regulatory updates in the first half of the year. FTD is a devastating disease, and the clinical unmet need remains substantial. We remain committed to advancing our program in the hope that we might one day offer patients and their families a therapy to redefine the course of their disease.”","length":678,"tagName":"p"},{"type":"text","content":"...